Melanotan II Guide: Tanning Peptide, Risks, Sexual Function & Dosing

Melanotan II is one of the most controversial peptides in the research space. Originally developed as a potential sunless tanning agent to reduce UV-related skin cancer risk, it was abandoned as a pharmaceutical due to its extensive off-target effects — many of which users later discovered could be desirable in their own right. Today it remains a research compound used for its tanning, sexual function, and appetite-suppressing effects, but with significant safety concerns that cannot be dismissed.

Understanding Melanotan II requires a clear-eyed look at both what it does well and the genuine risks it carries — particularly its effects on melanocytic lesions.

What Is Melanotan II?

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring melanocortin peptide. It is a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), unlike the more targeted PT-141, which was derived from it specifically for MC4R activity.

Melanotan II was originally developed at the University of Arizona in the 1990s by Dr. Victor Hruby's group. It was studied as a tanning agent (activating MC1R for melanin production) and as a potential male erectile dysfunction treatment before funding was discontinued and its further development as a pharmaceutical was abandoned.

Mechanism of Action

MC1R Agonism (Tanning)

Activation of melanocortin receptor 1 (MC1R) on melanocytes in the skin stimulates the production and release of eumelanin (dark melanin), causing skin darkening independent of UV exposure. This is the primary reason people use Melanotan II. Even minimal sun exposure is dramatically amplified in terms of melanin production.

MC4R Agonism (Sexual Function)

MC4R activation in the hypothalamus and limbic system drives sexual desire and penile erection through CNS mechanisms. This is the same receptor targeted by PT-141. Spontaneous erections are a well-documented effect of Melanotan II, often occurring several hours after injection.

MC3R/MC5R Agonism (Appetite, Other)

MC3R and MC5R activation contributes to Melanotan II's appetite-suppressing effects and may mediate some of its side effects. MC3R is involved in energy balance, and its activation can reduce food intake and body weight.

Broad Melanocortin Activity

Because Melanotan II activates multiple melanocortin receptors rather than targeting a specific one, it produces a wider range of effects — and side effects — than more targeted compounds like PT-141 or α-MSH analogs engineered for selectivity.

Dosing Protocol

• Loading dose: 0.25 mg subcutaneous injection initially (to assess tolerance)
• Maintenance dose: 0.25–0.5 mg per day until desired tan is achieved
• Maintenance (once tan is established): 0.5 mg 2–3 times per week
• Route: Subcutaneous injection (reconstituted in bacteriostatic water)
• Timing: Evening injection to minimize nausea during waking hours

Most users report a noticeable tan developing within 1–2 weeks at 0.5 mg/day with some UV exposure. The tan typically persists for weeks to months after discontinuation.

Tanning Effects

Melanotan II produces a deep, uniform tan that many users describe as more natural-looking than self-tanning products. Key characteristics:

• Amplifies UV response: Users tan significantly faster and more deeply with minimal sun exposure
• Freckles and existing pigmented spots darken prominently — this is both aesthetic (desired by some) and a concern
• Tan persists for months after stopping Melanotan II due to the longevity of melanocytes
• Works in fair skin types that normally burn rather than tan

The Moles/Nevi Problem: A Real Risk

This is where Melanotan II's risk profile becomes serious. The most significant safety concern with Melanotan II is its effect on melanocytic nevi (moles) and the potential to promote melanoma.

What the evidence shows:

• Multiple case reports document dramatic darkening, enlargement, and changes in pre-existing nevi during Melanotan II use
• New nevi appearing during use have been reported
• Several cases of melanoma in users have been documented, though causation vs. coincidence is difficult to establish
• MC1R activation is a known promoter of melanocyte proliferation and melanin production

The mechanism of concern: Melanotan II stimulates the same receptor (MC1R) that naturally drives melanocyte proliferation. In individuals with pre-existing atypical or dysplastic nevi (abnormal moles), this stimulation could theoretically promote malignant transformation. This concern has been raised by dermatologists and regulatory bodies.

Practical recommendations if using:

• Baseline and serial dermatological examination (full-body mole mapping)
• Stop immediately if any mole changes in size, shape, color, or borders (ABCDE criteria)
• Individuals with a personal or family history of melanoma, or with many atypical nevi, should not use Melanotan II

Regulatory Status

Melanotan II is not approved by the FDA, EMA, or any other major regulatory body. In many jurisdictions it is a grey-market research compound. The UK's MHRA has issued warnings against its use. Multiple countries have banned or restricted its sale.

It should not be confused with afamelanotide (Scenesse), an approved MC1R agonist for erythropoietic protoporphyria, which has a very different profile and extensive clinical oversight.

Side Effects

Very Common:

• Nausea (often severe in the first 30–60 minutes after injection, especially at higher doses)
• Facial flushing
• Spontaneous or prolonged erections (men) — this is dose-dependent and can be unwanted

Common:

• Darkening of moles and freckles (see above for significance)
• Appetite suppression
• Fatigue (can be profound at higher doses)
• Yawning (a peculiar but commonly reported effect of melanocortin agonism)

Less Common:

• Headache
• Elevated blood pressure (transient)
• Stretch marks becoming more visible due to differential melanin distribution

Serious Concerns:

• Melanoma risk (see above)
• Priapism (prolonged painful erection) in men — medical emergency requiring intervention

Comparison to PT-141

| Feature | Melanotan II | PT-141 | |---------|-------------|------| | Receptor selectivity | MC1R, MC3R, MC4R, MC5R | Primarily MC4R | | Tanning effect | Strong | Minimal | | Sexual function | Strong | Strong | | FDA approved | No | Yes (Vyleesi) | | Nausea | More severe | Less severe | | Mole/nevi risk | Significant concern | Much lower (less MC1R) | | Melanoma concern | Real | Much lower |

Frequently Asked Questions

Q: Does Melanotan II cause cancer? No definitive causal link between Melanotan II and melanoma has been established in controlled studies. However, multiple case reports document melanoma in users, and the mechanism (MC1R stimulation → melanocyte proliferation) raises legitimate concern. Anyone with atypical moles, a history of skin cancer, or high-risk phenotype should avoid it entirely.

Q: How long does the Melanotan II tan last? The tan typically persists for 1–3 months after stopping, as melanocytes already loaded with eumelanin continue to express pigment. It fades gradually as these cells turn over.

Q: Can women use Melanotan II? Yes, and many do for the tanning effects. The sexual function effects (desire, arousal) also occur in women. The nevi/melanoma risk applies equally. Some women also report changes in menstrual cycle timing, likely through MC4R/HPG axis interactions.

Q: Is there a safer tanning peptide alternative? Afamelanotide (Scenesse) is an approved MC1R agonist that works through a similar mechanism but is only available with a prescription for a specific medical condition. For purely cosmetic tanning without a medical indication, no safer peptide alternative is currently approved.

Q: What should I do if a mole changes while using Melanotan II? Stop Melanotan II immediately and see a dermatologist promptly. Any change in the appearance of a mole (size, shape, color, border irregularity, bleeding) should be evaluated without delay, regardless of its cause.